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Disease progression and outcomes in chronic kidney disease
and renal transplantation.
Background. It is unknown whether renal transplant recipi-
ents (RTR) have better outcomes and disease progression rates
compared to patients with chronic kidney disease (CKD) when
matched for the level of kidney function.
Methods. We analyzed data on 1762 patients with CKD (N
872) and RTR (N  890) over 16 years, applying the new
Kidney/Disease Outcomes Quality Initiative (K/DOQI) stag-
ing system for CKD in a single center retrospective study.
Patients were further divided based their native kidney disease.
We determined disease progression by the slope of creatinine
clearance decline and patient and kidney survival rates adjusted
for age, gender and stage of kidney function, using Cox propor-
tional hazards models.
Results. The overall rate of creatinine clearance decline in
patients with CKD was 6.6  8.7 mL/min/year compared to
1.9  4.7 mL/min/year in RTR (P  0.0001). The rate of
decline per stage of CKD was also significantly lower in RTR.
Whereas overall kidney survival was higher in RTR compared
to patients with CKD (49.6% vs. 17.2%, respectively, P 
0.001), patient survival was not statistically different between
the two groups (74.7% vs. 80.3%, respectively, P  0.25).
Conclusion. RTR had similar mortality rates compared to
patients with CKD despite enjoying slower rates of disease
progression and better kidney survival rates. These data suggest
that RTR are a unique subset of patients with CKD whose
comorbid conditions likely offset the potential benefits of
slower rates of progression.
The prevalence of end-stage renal disease (ESRD)
has risen rapidly in the United States during the past
decade and is expected to rise even further during the
next 10 years [1]. Moreover, the incidence of chronic
kidney disease (CKD) is markedly greater than that of
ESRD [1]. Clase, Garg, and Kiberd [2] recently esti-
mated that 58% of nondiabetic Americans have a glo-
merular filtration rate (GFR) less than 80 mL/min. Based
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on such data, the National Kidney Foundation (NKF)
Kidney Disease Outcomes Quality Initiative (K/DOQI)
task force published a five-stage CKD classification schema
to aid clinicians in identifying CKD-related complica-
tions and potentially intervene to delay disease progres-
sion [3].
One form of CKD that is often neglected in large
analyses is kidney transplantation. Renal transplant re-
cipients (RTR) have lower mortality rates than patients
with ESRD [4]. However, whether they also have better
outcomes compared to patients with CKD is unknown,
especially when matched for the level of kidney function.
Furthermore, there is little data comparing disease pro-
gression between these two patient populations. We hy-
pothesized that many RTR manifest CKD and that the
K/DOQI classification of CKD is applicable to these pa-
tients. We therefore applied this staging system to both
RTR and CKD patients and determined outcomes and
rates of progression between these two groups of patients.
METHODS
Patients
We performed a retrospective study of 1762 patients
at the University of Wisconsin Hospital and Clinics from
1985 to 2001. Data analysis was performed in accordance
with the Health Sciences Human Subjects Committee at
our Institution. Patients with CKD were selected if they
had a serum creatinine 1.3 mg/dL and were followed
for at least 1 year from the first elevated creatinine value.
RTR were selected from an ongoing study of patients
with long-term renal allograft function [5, 6]. The selec-
tion criterion was a functional renal allograft for at least
1 year. Demographic data were reported on age, gender,
ethnicity, cause of CKD, and kidney function. Outcomes
were defined by patient and kidney survival rates and
presented by Kaplan-Meier survival curves. Patient sur-
vival time was defined as the time interval between T1
(time of first visit for CKD patients and 1 year posttrans-
plant for RTR) and T2 (time of either last visit or death).
Kidney survival time was defined as the time interval
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Table 1. Characteristics and Kidney/Dialysis Outcomes Quality Initiative (K/DOQI) stages of patients with chronic kidney disease (CKD)
Ethnicity Creatinine Mean
K/DOQI Number Gender Age White clearance follow-up
Condition stages (%) male (%) (yearSD) (%) mL/min (yearSD)
All 1 71 (8) 62 (87) 4311a 63 (88) 10515 5.53.4a
2 240 (28) 175 (73) 4714a 228 (95) 728a 5.23.2a
3 403 (46) 218 (54) 5616a 363 (90) 458a 4.73.2a
4 138 (16) 66 (48) 6317a 123 (89) 244 3.12.4a
5 20 (2) 7 (36) 6713 20 (100) 113 2.32
Total/average 872 (100) 528 (60) 5417a 797 (92) 5324a 4.63.2a
Diabetes 1 25 (10) 21 (84) 4710a 24 (96) 10613 53.6a
2 86 (36) 63 (73) 4614a 86 (100) 728 4.62.9a
3 101 (43) 45 (45) 4814a 99 (98) 459a 4.12.8a
4 25 (10) 16 (64) 5115 20 (80) 244 1.61.5
5 2 (1) 0 (0) 533 2 (100) 135 10.1
Total/average 239 (100) 145 (60) 4714a 231 (97) 5924a 43a
Atherosclerotic kidney disease 1 12 (5) 9 (75) 4611a 10 (83) 10418 5.13a
2 56 (20) 40 (74) 5511a 49 (91) 729a 5.33.3a
3 140 (49) 80 (57) 6710a 138 (98) 458a 4.93.1a
4 67 (23) 32 (48) 7113 63 (94) 244 3.72.6
5 10 (3) 3 (30) 708 10 (100) 122 1.70.8
Total/average 283 (100) 164 (58) 6512a 270 (95) 4722a 4.63a
Glomerular disease 1 15 (10) 15 (100) 3513 13 (87) 1029 4.93.3a
2 41 (30) 30 (73) 4415a 40 (98) 7510 4.93a
3 64 (46) 39 (61) 5416a 57 (89) 468a 4.53.3a
4 19 (13) 7 (37) 5716 18 (95) 245 3.33.4
Total/average 139 (100) 91 (65) 4917a 128 (92) 5724a 4.53.2a
Interstitial disease 1 6 (7) 4 (66) 408 5 (83) 11329 5.42.6a
2 19 (24) 10 (53) 4515a 19 (100) 717 6.63.9a
3 38 (47) 13 (34) 5217a 38 (100) 468a 5.33.8a
4 16 (19) 5 (31) 4617 13 (81) 274 2.70.7a
5 2 (3) 1 (50) 5529 2 (100) 94 10.5
Total/average 81 (100) 33 (41) 5117a 77 (95) 5226a 5.13.6a
Polycystic kidney disease 1 9 (18) 9 (100) 399 9 (100) 10115 7.73.9
2 21 (42) 14 (67) 428 21 (100) 748 5.33.2a
3 14 (28) 6 (43) 4810a 13 (93) 458 5.42.1a
4 4 (8) 0 (0) 4617 4 (100) 274 2.70.7
5 2 (4) 2 (100) 5019 2 (100) 130.5 2.90.7
Total/average 50 (100) 31 (62) 4410a 49 (98) 6426 5.53.1
Other 1 4 (5) 4 (100) 444 4 (100) 1047 6.71.9
2 20 (25) 18 (90) 4815 18 (90) 686 6.23.4
3 46 (58) 30 (65) 4618 43 (93) 458 5.33.3
4 7 (8) 3 (43) 6216 6 (86) 243 2.51.3
5 3 (4) 1 (33) 6717 3 (100) 83 3.83.4
Total/average 80 (100) 56 (70) 5318 74 (93) 558 4.93.8
a P  0.05 for all corresponding values between CKD and renal transplant recipient. Stages with no patients are not shown.
between T1 (time of first visit for CKD patients and 1 year
posttransplant for RTR) and T2 (time of either last visit
or incidence of ESRD, retransplantation, or patient death
with a functional kidney).
Background nephropathy
Patients were divided based on the etiology of their
native kidney disease: diabetes mellitus, atherosclerotic
kidney disease, glomerular disease, interstitial disease,
polycystic kidney disease (PKD), and “other” nephropa-
thies, including nonkidney (lung, heart and liver) organ
transplant, congenital disease, cancer, human immuno-
deficiency virus (HIV) and unknown disease.
Determination of renal function, staging, and
disease progression
The Cockcroft-Gault estimation of creatinine clear-
ance  [(140  age)  (body weight)]/(serum creati-
nine  72) [7] was used to estimate kidney function. In
CKD patients, creatinine clearance 1 and creatinine clear-
ance 2 were estimated based on the first and last serum
creatinine values, respectively. In RTR, creatinine clear-
ance 1 was determined from the serum creatinine at
1 year posttransplant and creatinine clearance 2 from
the creatinine value at the last follow-up visit. Patients
were staged by the value of creatinine clearance 1 based
on the K/DOQI classification of CKD [3]. The slope be-
tween creatinine clearance 1 and creatinine clearance 2
was used to determine the rate of progression (mL/min/
year).
Statistical analysis
Two-sided t test or Wilcoxon’s rank sum test were
used when appropriate to analyze numerical data on age,
creatinine clearance, creatinine clearance slopes, and fol-
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Table 2. Characteristics and Kidney/Dialysis Outcomes Quality Initiative (K/DOQI) stages of renal transplant recipient (RTR)
Cadaveric Calcineurin Creatinine Mean
K/DOQI Number Gender Age transplantation inhibitors clearance follow-up
Condition stages (%) male (%) (yearSD) number (%) number (%) mL/min (yearSD)
All 1 132 (15) 88 (67) 3910 78 (59) 110 (83) 10715 8.33.3
2 412 (46) 264 (64) 4011 255 (62) 366 (89) 738 8.83.2
3 337 (38) 172 (51) 4313 235 (70) 313 (93) 507 8.23
4 9 (1) 0 (0) 5413 5 (56) 8 (89) 264 73.6
Total/average 890 (100) 524 (59) 4112 573 (64) 797 (90) 6922 8.53.2
Diabetes 1 26 (9) 18 (69) 399 20 (77) 23 (88) 10311 8.53
2 155 (52) 110 (72) 399 104 (68) 134 (88) 738 8.63
3 116 (39) 65 (56) 4010 80 (69) 107 (92) 506 8.43.2
Total/average 294 (100) 193 (66) 399 204 (69) 264 (90) 6617 8.53
Atherosclerotic kidney disease 1 14 (18) 11 (78) 437 10 (71) 12 (86) 10717 6.83.4
2 33 (43) 21 (64) 4818 18 (55) 29 (88) 7410 9.23.5
3 30 (39) 22 (73) 5112 26 (87) 28 (93) 507 7.63
Total/average 77 (100) 54 (70) 4812 54 (70) 69 (90) 7123 8.13.3
Glomerular disease 1 61 (20) 43 (70) 3810 30 (49) 50 (82) 10816 8.23.2
2 129 (43) 78 (60) 3911 64 (50) 115 (89) 748 8.43.2
3 101 (34) 52 (51) 4313 64 (63) 93 (92) 497 83.2
4 6 (3) 0 (0) 5015 3 (50) 5 (83) 265 6.13.3
Total/average 297 (100) 173 (58) 4012 161 (54) 263 (89) 7224 8.23.2
Interstitial disease 1 8 (15) 4 (50) 408 5 (63) 7 (88) 11115 8.53.7
2 22 (41) 12 (55) 3711 9 (41) 20 (91) 728 9.73.4
3 23 (42) 7 (30) 4215 11 (48) 22 (96) 516 8.62.7
4 1 (2) 0 (0) 55 0 (0) 1 (100) 25 13
Total/average 54 (100) 23 (43) 4013 25 (46) 50 (93) 6823 9.13.1
Polycystic kidney disease 1 9 (12) 5 (55) 468 5 (55) 8 (89) 10712 8.73.1
2 32 (42) 20 (63) 4710 27 (84) 31 (97) 726 9.63
3 33 (43) 15 (45) 5610 29 (88) 33 (100) 488 8.22.8
4 2 (6) 0 (0) 621 2 (100) 2 (100) 264 6.62.2
Total/average 76 (100) 40 (53) 5111 63 (83) 74 (97) 6421 8.83
Other 1 14 (15) 10 (71) 3213 8 (57) 10 (71) 10912 8.74.3
2 44 (48) 27 (61) 3815 24 (55) 37 (84) 719 8.93.8
3 34 (37) 15 (44) 3813 22 (65) 30 (85) 498 8.13.3
Total/average 92 (100) 52 (56) 3610 54 (59) 77 (84) 706 8.63.4
Stages with no patients are not shown.
low-up years. Fisher’s exact test was performed to ana-
lyze categorical data. NCSS/PASS 2000 Statistical Sys-
tems Software (Kaysville, UT, USA) was used for this
analysis. Patient and kidney survival rates, as well as the
relative risk of death and kidney failure, were assessed
using Cox proportional hazards models, adjusting for
age, gender, and stage of kidney function. Relative risks
were expressed as the probability of death or kidney
failure among CKD patients compared to RTR. The sur-
vival data analysis was carried out in S-PLUS (MathSoft
1997). A P value of 0.05 was considered significant.
RESULTS
Demographics
Tables 1 and 2 depict the demographic data in patients
with CKD and RTR based on primary kidney disease
and stage of CKD. There were 1762 patients during the
1985 to 2001 time period (872 patients with CKD and
890 with RTR).
CKD stage distribution
Patient distribution based on creatinine clearance 1
value showed that most patients belonged to stages 2
Fig. 1. Distribution of patients with chronic kidney disease (CKD)
and renal transplant recipients (RTR) matched for the level of kidney
function.
and 3. Indeed, 74% of patients with CKD and 84%
of RTR had an estimated creatinine clearance between
30 mL/min and 89 mL/min (Fig. 1). This distribution
pattern was found among nearly all subgroups (Tables
1 and 2). There were no RTR in stage 5.
Gender
Approximately 60% of study subjects were male. Male
gender, in fact, predominated among all subgroups ex-
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cept in patients with interstitial nephritis, where female
patients accounted for 57% and 59% of the RTR and
CKD patients, respectively.
Age and ethnicity
RTR were significantly younger than patients with
CKD in nearly all stages of CKD (Table 1). Overall, the
average age of RTR was 41  12 years vs. 54  17 years
for CKD patients (P  0.0001). The exception was in
patients with PKD where RTR were older (51 11 years
vs. 44  10 years, P  0.0001). More than 90% of our
CKD patients and RTR were Caucasian.
Follow-up and other characteristics
Patients lost from follow-up were those for whom the
final outcome was unknown as they failed to present
to their last clinic appointment and the examination of
medical records could not determine whether these pa-
tients had reached ESRD, expired, or moved. Thus de-
fined, the rate of follow-up was 86% for both groups
during the study period (data not shown). The follow-up
interval was defined by the time period between creati-
nine clearance 1 and creatinine clearance 2 and it was
longer for RTR compared to other patients with CKD
(8.5  3.2 vs. 4.6  3.2 years, respectively, P  0.0001).
In the considered time-period of 1985 to 2001, 64% of
RTR received cadaver kidneys and a large majority
(90%) received calcineurin inhibitors (cyclosporine A
or tacrolimus).
Calculated creatinine clearance
(Cockcroft-Gault assessment)
Average first visit creatinine clearance values ranged
between 47  22 mL/min and 64  26 mL/min in CKD
patients (Table 1). The average creatinine clearance lev-
els for RTR were higher and ranged from 64  21 mL/
min and 72  24 mL/min (P  0.0001) except for those
with PKD [64  26 mL/min vs. 64  21 mL/min (P 
NS)] (Table 1). Last visit creatinine clearance estima-
tions (creatinine clearance 2) ranged between 25 15 ml/
min and 41  17 mL/min for CKD patients, whereas
they varied between 52  22 mL/min and 70  33 mL/
min in the RTR group. The creatinine clearance 2 values
were statistically higher in RTR compared to patients
with CKD for each disease state (P  0.0001) (data not
shown).
Disease progression
Overall, the mean rate of creatinine clearance decline
in all patients with CKD was 6.6  8.7 mL/min/year
compared to 1.9  4.7 mL/min/year in RTR (P 
0.0001). Figure 2 depicts the creatinine clearance slope
(mL/min/year) on the y-axis and the baseline creatinine
clearance stage on the x-axis in a format similar to that
reported by Hunsicker et al [8]. Each panel represents
Fig. 2. Disease progression in patients with chronic kidney disease
(CKD) and renal transplant recipients (RTR) matched for the level of
kidney function. Abbreviations are: CCR, creatinine clearance; DM,
diabetes mellitus; GD, glomerular disease; ID, interstitial disease; PKD,
polycystic kidney disease.
disease progression in patients with CKD and RTR,
based on the background nephropathy. The mean rate
of creatinine clearance decline was faster in patients with
CKD compared to RTR for all stages of kidney disease
and all nephropathy subgroups. Notably, disease pro-
gression was faster in earlier stages of kidney disease for
most subgroups.
The average rate of creatinine clearance decline for
all CKD patients was -11  12 mL/min/year in stage 1
vs. 3.8  7 mL/min/year for RTR (P  0.05). The
slopes for stages 2 to 5 in CKD patients were 8.4 
10 mL/min/year, 5.4  7.4 mL/min/year, 5.7  5.6
mL/min/year, and1.5 8.5 mL/min/year, respectively.
RTR had significantly less negative slopes in stages 2 to
4: 2  4 mL/min/year, 1  3.7 mL/min/year, and
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Fig. 3. Patient survival in patients with chronic
kidney disease (CKD) and renal transplant recipi-
ents (RTR). (A ) Survival adjusted for age and
gender. (B ) Survival adjusted for age, stage, and
gender. (C ) Survival per stage of kidney function,
adjusted for age and gender.
1 3.3 mL/min/year, respectively (P 0.05) (Fig. 2A).
We then compared the average rate of disease progres-
sion in all RTR to different subgroups of patients with
CKD. We divided CKD patients into two groups: those
with systemic diseases (diabetes mellitus and atheroscle-
rotic kidney disease) (Fig. 2B) and those with glomerular
disease, renal-limited vaculitides, interstitial diseases,
and polycystic disease (Fig. 2C). Interestingly, at all lev-
els of kidney function, the rate of progression was sig-
nificantly slower in RTR (P  0.05 for all). The only
exception was stage 3 for interstitial nephritis where the
difference was not statistically different.
Outcome
Patient and kidney survival probabilities were de-
picted by Kaplan-Meier survival curves in Figures 3 and
4, respectively. Table 3 shows the survival rates, relative
risks, 95% confidence intervals, and P values for patient
death or kidney failure in patients with CKD compared
to RTR, and the observation period. Patient survival
analysis by Cox proportional hazards models revealed
that between age, gender, and stage of kidney function,
only age had a significant effect on mortality (P  0.01).
Interestingly, after more than 12 years of observation,
the overall patient survival was not significantly different
between patients with CKD and RTR (80.3% vs. 74.7%,
respectively, RR  0.79, 95% CI 0.56 to 1.17, P  0.25).
Subgroup analysis demonstrated that stage 3 CKD pa-
tients had a significantly lower risk of death than RTR
(RR  0.55, 95% CI 0.32 to 0.94, P  0.02).
Kidney survival analysis showed that whereas age,
gender, and stage of kidney function had no significant
effect on the overall kidney survival rates, the CKD/
RTR status had a significant effect. Patients with CKD
had higher rates of kidney failure compared to RTR.
The overall risk of kidney failure, adjusted for age, gen-
der, and stage of kidney function was more than three
times higher in patients with CKD (RR  3.2, 95% CI
2.66 to 3.80, P  0.001). This difference was significant
in all but stage 1 CKD.
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Fig. 4. Kidney survival in patients with chronic
kidney disease (CKD) and renal transplant
recipients (RTR). (A ) Survival adjusted for
age and gender. (B ) Survival adjusted for age,
stage, and gender. (C ) Survival per stage of
kidney function, adjusted for age and gender.
DISCUSSION
We hypothesized that RTR represent a unique sub-
group of CKD patients. To address this hypothesis, we
compared rates of progression and outcomes in a group
of patients with CKD to those in a group of RTR. The
most striking finding was that overall patient survival, ad-
justed for age, gender, and stage of kidney function was
similar between all patients with CKD (non-RTR and
RTR) despite differences in kidney survival and dis-
ease progression. The United States Renal Data System
(USRDS) and the United Network for Organ Sharing
(UNOS) registries demonstrate that mortality rates in
patients with ESRD and RTR are 25% to 27% and 4%
to 6% per year, respectively, during the first 5 years
following the initiation of dialysis or transplantation [9].
It has been also been shown that RTR have better out-
comes than patients with ESRD [4]. Our data demon-
strate that RTR do not have better survival rates com-
pared to patients with CKD. Interestingly, mortality
rates in stage III were significantly higher among RTR.
This finding might have key implications as close to 40%
RTR at our institution can be classified as stage III. One
factor that almost certainly contributes to this outcome
is the lead-time disease and comorbidity burden that
affects RTR (Fig. 5). The significant difference in the
rates of progression between non-RTR and RTR CKD
patients further reinforces this point. It suggests that kid-
ney disease “vintage” may be more influential on mortal-
ity at any given level of function than the rate of loss of
function. RTR have indeed survived their first encounter
with CKD. The congruency of death rates also suggests
that other factors such as immunosuppression could play
a role in equilibrating death rates between RTR and
non-RTR CKD patients for any level of CKD.
Our study also highlights novel data regarding pro-
gression per se in RTR. We noted that progressive loss
of kidney function was more rapid in non-RTR CKD
patients compared to RTR, despite the same initial level
of kidney function. A number of factors, occurring prior
to or after kidney transplantation could explain this dif-
ference. Indeed, kidneys with similar creatinine clear-
ance might have different histopathologic findings (e.g.,
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Table 3. Patient and kidney survival rates in patients with chronic kidney disease (CKD) and renal transplant recipient (RTR)
Overall survival rates, adjusted for age, gender and stage of kidney function
Follow-up years Survival rate % RR 95% CI P value
Patient survival CKD 12.6 80.3 0.79 (0.56–1.17) 0.25
RTR 13.3 74.7
Kidney survival CKD 13.5 17.2 3.2 (2.66–3.80) 0.001
RTR 14.3 49.6
Patient survival, per stage of kidney function, adjusted for age and gender
Follow-up years Survival rate % RR 95% CI P value
Stage 1 CKD 6.2 94.6 0.52 (0.14–1.88) 0.32
RTR 10.2 81
Stage 2 CKD 10.2 89.1 1.16 (0.62–2.19) 0.65
RTR 13.3 84.6
Stage 3 CKD 12.6 79 0.55 (0.32–0.94) 0.02
RTR 13 65.7
Stage 4 CKD 11.2 9.8 4.87 (0.55–43.2) 0.16
RTR 8.2 83.8
Kidney survival, per stage of kidney function, adjusted for age and gender
Follow-up years Survival rate % RR 95% CI P value
Stage 1 CKD 12.7 38.1 1.69 (0.92–3.1) 0.09
RTR 14 49.8
Stage 2 CKD 12.1 26.8 3.50 (2.58–4.74) 0.001
RTR 14.3 57.7
Stage 3 CKD 13.5 12.9 3.17 (2.44–4.12) 0.001
RTR 14 46.6
Stage 4 CKD 11.2 4.9 2.86 (1.12–7.39) 0.03
RTR 8.2 47
Fig. 5. Application of the Kidney/Dialysis Outcomes Quality Initiative
(K/DOQI) classification of chronic kidney disease (CKD) to patients
with CKD and renal transplant recipients (RTR).
variable glomerular, vascular, and/or tubulointerstitial
injury). The involvement of different components of re-
nal parenchyma in the disease process might have differ-
ent impacts on the rate of progression. Donor age could
also affect progression, given that Cockcroft-Gault for-
mula estimates creatinine clearance based on the recipient
and not the donor’s age. Further, kidneys with compara-
ble creatinine clearance could have different functional
reserves, allowing them better adaptation to stress and
further injury. Finally, potential benefits from immuno-
suppression have to be considered, although 90% of
RTR at our center received calcineurin inhibitors during
the study period, and the nephrotoxic effects of these
drugs have been well established.
The role of comorbid factors further strengthens the
hypothesis that kidney transplantation is a unique form
of CKD. Hypertension, hyperglycemia, dyslipidemia, ane-
mia, and renal osteodystrophy are prevalent in RTR [10].
Yorgin et al [11] recently reported that more than 25% of
RTR are anemic by the fifth posttransplant year. Anemia
treatment in this population may stabilize transplant
function [12], similar to its effects in de novo chronic kid-
ney disease [13]. Secondary hyperparathyroidism per-
sists after transplantation, because involution of para-
thyroid gland hyperplasia is slow and may never occur,
despite reestablishment of some degree of renal function
[14]. In RTR, calcium and vitamin D therapy may accel-
erate the return to basal parathyroid hormone secretion
[15] as they do in patients with CKD, and even delay
disease progression [16]. The 1985 to 2001 time period
corresponds to the new era of immunosuppression and
management of kidney failure. A subgroup analysis of
patients during this period revealed that approximately
10% of patients with RTR vs. 25% of patients with CKD
were on erythropoietin and 25% of RTR vs. 40% CKD
patients were on either angiotensin-converting-enzyme
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(ACE) inhibitors or angiotensin receptor blockers (ARBs).
However, these data could not be generalized to our
patient population. A large parallel prospective case
(RTR) cohort (non-RTR CKD) analysis that adjusts for
many of the aforementioned variables (comorbid factors,
drugs) will truly be necessary to validate the conclusion
that RTR are a unique group of CKD.
We used the Cockcroft-Gault formula to assess pro-
gression, rather than rely on serum creatinine measure-
ments alone. Mathematical assessments of kidney func-
tion include Cockcroft-Gault [7], Modification of Diet
in Renal Disease (MDRD) [17], and Nankivell et al [18]
(specifically for transplant recipients) formulas. How-
ever, we strove for uniformity in applying a formula
across all populations. Transplant-specific formulas may
not apply to the non-RTR CKD. Moreover, the clinical
practice nature of this study obviated prospective collec-
tion of all variables to make accurate calculations, using
other formulas. Thus, given its practicality and accuracy
[19], while acknowledging its limitations, we used the
Cockcroft-Gault formula in our study.
This study is limited in other ways as are all retrospec-
tive single center studies. Local medical practice pat-
terns may have influenced decisions, including timing of
ESRD treatment initiation. Our population is skewed
toward Caucasian patients (for the most part of Northern
European descent). Finally, few studies could adjust for
all of changes in the fields of medicine and transplanta-
tion that have occurred in the past 25 years.
CONCLUSION
Our study utilizes the K/DOQI classification of CKD
for RTR and represents therefore a novel application of
the kidney disease classification system. We found that
disease progression was faster in patients with CKD
compared to RTR. Mortality rates, however, were simi-
lar between the two groups. These findings argue for a
similar approach in both groups of patients to prevent
mortality.
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